U.S. Markets closed

Should You Be Tempted To Sell Global Cord Blood Corporation (NYSE:CO) At Its Current PE Ratio?

Michael Canly

This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning the link between Global Cord Blood Corporation (NYSE:CO)’s fundamentals and stock market performance.

Global Cord Blood Corporation (NYSE:CO) trades with a trailing P/E of 27.8x, which is higher than the industry average of 21.9x. Although some investors may jump to the conclusion that you should avoid the stock or sell if you own it, understanding the assumptions behind the P/E ratio might change your mind. In this article, I will deconstruct the P/E ratio and highlight what you need to be careful of when using the P/E ratio. Check out our latest analysis for Global Cord Blood

Breaking down the Price-Earnings ratio

NYSE:CO PE PEG Gauge June 26th 18

P/E is often used for relative valuation since earnings power is a chief driver of investment value. It compares a stock’s price per share to the stock’s earnings per share. A more intuitive way of understanding the P/E ratio is to think of it as how much investors are paying for each dollar of the company’s earnings.

P/E Calculation for CO

Price-Earnings Ratio = Price per share ÷ Earnings per share

CO Price-Earnings Ratio = CN¥65.43 ÷ CN¥2.354 = 27.8x

The P/E ratio isn’t a metric you view in isolation and only becomes useful when you compare it against other similar companies. We preferably want to compare the stock’s P/E ratio to the average of companies that have similar features to CO, such as capital structure and profitability. One way of gathering a peer group is to use firms in the same industry, which is what I’ll do. At 27.8x, CO’s P/E is higher than its industry peers (21.9x). This implies that investors are overvaluing each dollar of CO’s earnings. Therefore, according to this analysis, CO is an over-priced stock.

Assumptions to watch out for

Before you jump to the conclusion that CO should be banished from your portfolio, it is important to realise that our conclusion rests on two assertions. The first is that our “similar companies” are actually similar to CO, or else the difference in P/E might be a result of other factors. For example, if you compared higher growth firms with CO, then its P/E would naturally be lower since investors would reward its peers’ higher growth with a higher price. The second assumption that must hold true is that the stocks we are comparing CO to are fairly valued by the market. If this is violated, CO’s P/E may be lower than its peers as they are actually overvalued by investors.

What this means for you:

Since you may have already conducted your due diligence on CO, the overvaluation of the stock may mean it is a good time to reduce your current holdings. But at the end of the day, keep in mind that relative valuation relies heavily on critical assumptions I’ve outlined above. Remember that basing your investment decision off one metric alone is certainly not sufficient. There are many things I have not taken into account in this article and the PE ratio is very one-dimensional. If you have not done so already, I highly recommend you to complete your research by taking a look at the following:

  1. Future Outlook: What are well-informed industry analysts predicting for CO’s future growth? Take a look at our free research report of analyst consensus for CO’s outlook.
  2. Past Track Record: Has CO been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of CO’s historicals for more clarity.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.